Eastwood Bio-Medical Canada Inc.

EBM

CA27783W1059

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 14:52:23 13/05/2024 BST			5-day change	1st Jan Change
0.55 ^CAD	-37.50%		0.00%	0.00%

04-02	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
02-29	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI

Eastwood Bio-Medical Canada Inc. Provides Revenue Guidance for the Fourth Quarter Ended October 31, 2018

November 14, 2018

Eastwood Bio-Medical Canada Inc. announced that the estimates from initial unaudited calculations a revenue growth of roughly over 350% for fourth quarter ending October 31, 2018.

Latest news about Eastwood Bio-Medical Canada Inc.

Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	04-02	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	02-28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	29/09/23	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	30/06/23	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	31/03/23	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	27/02/23	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	27/02/23	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	29/09/22	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	29/06/22	CI
Eastwood Bio-Medical Canada Inc.(TSXV:EBM) dropped from S&P/TSX Venture Composite Index	18/04/22	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	01/04/22	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2021	28/02/22	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	27/02/22	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2021	28/09/21	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2021	29/06/21	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2020	01/03/21	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	28/02/21	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2020	29/09/20	CI
Eastwood Bio-Medical Canada Inc. Appoints Youngsoo Kim as the New Chief Executive Officer	03/09/20	CI
Eastwood Bio-Medical Canada Inc. Announces Executive Change	03/09/20	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2020	29/06/20	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2020	30/03/20	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2019	26/02/20	CI
Eastwood Bio-Medical Canada Inc. Partners with Ruiyan	22/01/20	CI
Eastwood Bio-Medical Canada Inc. Introduces New Products	07/10/19	CI

Chart Eastwood Bio-Medical Canada Inc.

Duration

Period

More charts

Eastwood Bio-Medical Canada Inc. is engaged in marketing and distributing natural health products in North America. It is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief.

Sector

Pharmaceuticals

Calendar

26/06/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
EASTWOOD BIO-MEDICAL CANADA INC.	0.00%	27.71M
DONG-E-E-JIAO CO.,LTD.	+38.28%	6.07B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.91%	4.42B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+5.14%	3.26B
TASLY PHARMACEUTICAL GROUP CO., LTD	-14.63%	3B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-4.12%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+42.14%	1.89B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.63%	1.63B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-2.71%	1.6B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.26%	1.54B